Navigation Links
Atrium Responds to Bard Suit
Date:8/17/2010

HUDSON, N.H., Aug. 18 /PRNewswire/ -- Atrium Medical Corporation was recently named as a defendant, along with Endologix, Inc., of Irvine, CA, in a lawsuit brought by C.R. Bard in U.S. District Court in Arizona.  The suit involves a patent, U.S. No. 6,436,135, issued to Bard in 2002 related to prosthetic vascular grafts made of ePTFE (expanded polytetrafluoroethylene). Atrium has been involved in discussions with Bard management regarding this patent for several years.

The patent was filed in 1974 and has been the subject almost continuous litigation for nearly thirty years between Bard and W. L. Gore Associates before the U.S. Patent Office and the courts. That litigation is still ongoing, and involves questions about the validity and scope of the patent that will ultimately have to be resolved by the court of appeals. Final resolution, however, will take upwards of two years or more.

Steve Herweck, Chairman and Chief Executive Officer of Atrium, said, "Atrium's management has every intention to resolve this issue in the best interest of our firm, employees and shareholders. Atrium remains committed to our almost 30 year history and practice of not knowingly violating anyone's intellectual property. Litigation by many companies today has unfortunately become an integral and daily part of business practice by many, including those in the diverse healthcare industry. We remain confident in attaining a resolution to this suit filed by Bard, and remain steadfast in our commitment to uninterrupted supply of all of our products, and our legacy of the 'best-in-the-industry' customer service to our customers."

Endologix also responded to the suit in a statement last week, saying it was confident its products do not infringe Bard's patent.

About Atrium

Founded in 1981, Atrium is a diversified healthcare provider dedicated to innovation, research and development, state-of-the-art manufacturing, customer service, and clinical education. From the cardiac cath-lab to the operating room, Atrium offers a diversified portfolio of critical care products leading the way to brighter, more clinically effective solutions in cardiovascular disease, soft tissue repair and critical care management.


'/>"/>
SOURCE Atrium Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
2. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
3. Roche responds to announcement of IDEAL hepatitis C trial results
4. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
5. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
6. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
7. EPSScentral Responds to Pandemic Alert
8. Endologix Responds to Alleged Patent Infringement
9. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
10. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
11. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Lake Park Dental ... by using Invisalign® in Lutz, FL. With the help of this highly-effective, ... aesthetics with fewer potential complications, more discretion and less pain. , Drs. Sarah ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Buyers and ... recreational users to dispensaries and head shops –can’t help but be heartened by the ... the tell-tale cannabis odor aptly described as “skunk smell.” At last they can ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection ... Pink is proud to announce Katie Thiede as their new Chief Executive Officer. In January, ... Chairman of the Board and launched a national search to find a visionary new leader ...
Breaking Medicine News(10 mins):